论文部分内容阅读
应用固相酶联免疫洲定方法(ELISA),检测351例不同类型肝病患者血清丙型肝炎病毒抗体(抗-HCV)。输血后非甲非乙型肝炎(NANBH)、散发性NANBH和非乙型肝硬化抗-HCV阳性率分别为86%、34.9%和76.2%;28例急性甲肝均阴性;乙肝患者为23.3%;原发性肝癌为16.0%。有输血史乙肝患者抗-HCV阳性率高于无输血史者。提示除甲肝外,各类肝病患者均为HCV高危人群。输血液制品是乙肝合并丙肝的主要原因。
Serum hepatitis C virus antibody (anti-HCV) was detected in 351 patients with different types of liver disease by solid-phase enzyme-linked immunosorbent assay (ELISA). The positive rates of non-A non-B hepatitis (NANBH), sporadic NANBH and non-B cirrhosis were 86%, 34.9% and 76.2% respectively after transfusion; 28 cases were negative for both A and B; 23.3% Primary liver cancer was 16.0%. Blood transfusion history of hepatitis B patients with anti-HCV positive rate was higher than those without transfusion history. Tip in addition to hepatitis A, all kinds of liver disease patients are HCV high-risk groups. Transfusion of blood products is the main reason for hepatitis B and hepatitis C.